Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Suzanne Shusterman, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Mack JW, Uno H, Twist CJ, Bagatell R, Rosenberg AR, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park JR, Cohn SL, Fernandez JH, Diller LR, Shusterman S. Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. J Pain Symptom Manage. 2020 Apr 30. PMID: 32360991.
    Citations:    
  2. Hillier K, Hughes A, Shamberger RC, Shusterman S, Perez-Atayde AR, Wassner AJ, Iafrate AJ, Dubuc A, Janeway KA, Rothenberg SM, Cox MC, Randolph GW, Wirth LJ, Tsai H, Church A, DuBois SG. A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707. PMID: 31650892.
    Citations:    
  3. Mack JW, Cronin AM, Uno H, Shusterman S, Twist CJ, Bagatell R, Rosenberg A, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park J, Cohn SL, Levine A, Taddei S, Diller LR. Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer. 2020 01 15; 126(2):416-424. PMID: 31584705.
    Citations:    
  4. Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, Servaes S, London WB, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clin Cancer Res. 2019 10 15; 25(20):6044-6051. PMID: 31358541.
    Citations:    
  5. Gauguet JM, Pace-Emerson T, Grant FD, Shusterman S, DuBois SG, Frazier AL, Voss SD. Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma. Pediatr Blood Cancer. 2017 Nov; 64(11). PMID: 28449267.
    Citations: 1     Fields:    Translation:Humans
  6. Li R, Polishchuk A, DuBois S, Hawkins R, Lee SW, Bagatell R, Shusterman S, Hill-Kayser C, Al-Sayegh H, Diller L, Haas-Kogan DA, Matthay KK, London WB, Marcus KJ. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277. PMID: 28068235.
    Citations: 1     Fields:    Translation:Humans
  7. Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CWM, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. PMID: 26822149.
    Citations: 22     Fields:    
  8. Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KG. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015 Oct; 64(10):1251-60. PMID: 26105625.
    Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
  9. Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014 Oct; 61(10):1792-7. PMID: 24962521.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  10. Bernson-Leung M, Ananth P, Shusterman S. Neuroblastoma presenting as facial nerve palsy and bulging tympanic membrane. Clin Pediatr (Phila). 2015 Feb; 54(2):183-5. PMID: 24817076.
    Citations:    Fields:    Translation:Humans
  11. Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014 Jun; 61(6):990-6. PMID: 24347462.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  12. Markelewicz RJ, Lorenzen WA, Shusterman S, Grant FD, Fahey FH, Treves ST. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy. Clin Nucl Med. 2013 Aug; 38(8):604-7. PMID: 23797228.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  13. Grupp SA, Prak EL, Boyer J, McDonald KR, Shusterman S, Thompson E, Callahan C, Jawad AF, Levine BL, June CH, Sullivan KE. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res. 2012 12 15; 18(24):6732-41. PMID: 23092876.
    Citations: 14     Fields:    Translation:HumansCells
  14. DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, Baruchel S, Glade-Bender J, Ivy P, Adamson PC, Blaney SM. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1021-7. PMID: 22179104.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  15. Shusterman S, Grant FD, Lorenzen W, Davis RT, Laffin S, Drubach LA, Fahey FH, Treves ST. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience. Semin Nucl Med. 2011 Sep; 41(5):354-63. PMID: 21803185.
    Citations: 2     Fields:    Translation:Humans
  16. Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 01; 17(15):5113-22. PMID: 21690570.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  17. Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1057-65. PMID: 21340605.
    Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
  18. Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JJ, Adamson PC. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol. 2011 Mar 01; 29(7):839-44. PMID: 21263099.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  19. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM. Genotypes of NK cell KIR receptors, their ligands, and Fc? receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 01; 70(23):9554-61. PMID: 20935224.
    Citations: 65     Fields:    Translation:HumansCellsCTClinical Trials
  20. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75. PMID: 20921469.
    Citations: 76     Fields:    Translation:HumansCTClinical Trials
  21. Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009 Mar 01; 27(7):1020-5. PMID: 19171714.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  22. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006 Jun 15; 66(12):6050-62. PMID: 16778177.
    Citations: 82     Fields:    Translation:Humans
  23. BAnsal MM, Wang Q, Zhao H, Courtright J, King R, Rhodin N, Shusterman S and Maris JM. Expression profiling identifies BAI2, an endogenous inhibitor of angiogenesis, as a traget for somatic inactivation in high-risk neuroblastoma. Advances in Neuroblastoma Research Proceedings. 2006; 73.
  24. Maris JM and Shusterman S. Neuroblastoma. Holland JC and Frei E, editors. Cancer Medicine. 2006.
  25. Matthay K, Quach A, Franc B, Huberty J, Groshen S, Shusterman S, Veatch J, Brophy B, Yanik G, Maris JM. 131I-Metaiodobenzylguanidine(131I-MIBG) double infusion with autologous stem cell transplant (ASCT) for neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) study. Advances in Neuroblastoma Research Proceedings. 2006; 123.
  26. Shusterman S, Maris JM. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett. 2005 Oct 18; 228(1-2):171-9. PMID: 15927358.
    Citations: 13     Fields:    Translation:Humans
  27. Morowitz MJ, Barr R, Wang Q, King R, Rhodin N, Pawel B, Zhao H, Erickson SA, Sheppard GS, Wang J, Maris JM, Shusterman S. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin Cancer Res. 2005 Apr 01; 11(7):2680-5. PMID: 15814649.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  28. Bansal MM, Wang Q, Zhao H, King R, Rhodin N, Shusterman S and Maris JM. Somatic Inactivation of brain-specific angiogenesis inhibitor-2 (BAI2) during the malignant evolution of high-risk neuroblastoma. Pediatric Blood and Cancer. 2005; 44(6).
  29. Matthay KK, Huberty J, Hawkins R, Yanik G, Charron M, Groshen S, Seeger RC, Shusterman S and Maris JM. 131I-MIBG double infusiton with autologous stem cell transplant (ASCT) for neuroblastoma - a New Approaches to Neuroblastoma Therapy (NANT) study. Advances in Neuroblastoma Research Proceedings. 2004; 65.
  30. Wang Q, Diskin S, Shusterman S, Rappaport E, Mosse Y, Khazi D, Winters C, Hii G, Attiyeh EF, King RL, Rhodin N, Grant G, Matthay KK, London WB and Maris JM. Genome-wide transcriptome analysis for neuroblastoma gene discovery and refinement of clinical risk group prediction. Advances in Neuroblastoma Research Proceedings. 2004; 103.
  31. Morowitz M, Shusterman S, Mosse Y, Hii G, Winter CL, Khazi D, Wang Q, King R, Maris JM. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction. Mod Pathol. 2003 Dec; 16(12):1248-56. PMID: 14681326.
    Citations: 5     Fields:    Translation:HumansCells
  32. Wang J, Sheppard GS, Lou P, Kawai M, BaMaung N, Erickson SA, Tucker-Garcia L, Park C, Bouska J, Wang YC, Frost D, Tapang P, Albert DH, Morgan SJ, Morowitz M, Shusterman S, Maris JM, Lesniewski R, Henkin J. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15; 63(22):7861-9. PMID: 14633714.
    Citations: 10     Fields:    Translation:HumansAnimals
  33. Wang Q, Hii G, Shusterman S, Mosse Y, Winter CL, Guo C, Zhao H, Rappaport E, Hogarty MD, Maris JM. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Cancer Res. 2003 Apr 01; 63(7):1631-5. PMID: 12670915.
    Citations: 5     Fields:    Translation:HumansCells
  34. Maris JM and Shusterman S. Neuroblastoma. Holland JC and Frei E, editors. Cancer Medicine. 2003; 2263-76.
  35. Fang J, Stern JW, Shusterman S, Alcorn K, Pierson G, Barr R, Pawel B, Diller L, Maris JM, and Grupp SA. Transplantation in Hematology and Oncology II. 2003; 283-98.
  36. Shusterman S and Manno CS. Transfusion of the patient with congenitally aquired coagulation defects. Hillyer CD and Silbersteing LE, editors. Principles of Blood Banking and Transfusion Medicine. 2003; 291-306.
  37. Morowitz MJ, Shusterman S, Barr R, Wang Q, King R, Pawel B, Zhao H, Erickson SA, Sheppard GS, Wang J and Maris JM. A reversible methionine aminopeptidase inhibitor potently inhibits growth of human neuroblastoma in xenotransplantation models. American Association fo Cancer Research Proceedings. 2003; 44:809.
  38. Mosse Y, Greshock J, Khazi D, Hii G, Wang Q, Morowitz MJ, Winter C, Shusterman S, Weber BL and Maris JM. Functional genomic analysis of neuroblastoma for high resolution mapping of 11q deletions. American Association for Cancer Research Proceedings. 2003; 44:1394.
  39. Keshelava N, Chen P, Waidyartatne SN, Shusterman S, Maris JM, Seeger RC, Triche TJ and Reynolds P. Increased incidence of TP53 mutations in post-treatment neuroblastomas. American Association for Cancer Research Proceedings. 2003; 44:809.
  40. Shusterman S, King RL, Rappaport E, Barr E and Maris JM. Discovery of antiangiogenic targets induced by chemotherapy in a murine model of human neuroblastoma. American Association for Cancer Research Proceedings Late Breaking Abstracts. 2003.
  41. Maris JM, Weiss MJ, Mosse Y, Hii G, Guo C, White PS, Hogarty MD, Mirensky T, Brodeur GM, Rebbeck TR, Urbanek M, Shusterman S. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res. 2002 Nov 15; 62(22):6651-8. PMID: 12438263.
    Citations: 13     Fields:    Translation:HumansCells
  42. Maris JM, Guo C, Hii G, Wang Q, Morowitz MJ, Winter C, Mosse Y and Shusterman S. A combined functional and expression profiling strategy for isolating neuroblastoma suppresso genes on chromosome 11. American Association for Cancer Research Proceedings. 2002; 43:343.
  43. Shusterman S, Morowitz MJ, Grupp SA, Barr R, Pawel B, Zhao H, Wang Q, Weiss WA and Maris JM. Angiogenesis inhibition is an effective adjuvant therapeutic strategy in neuroblastoma (NB) preclinical models. Advances in Neuroblastoma Research Proceeddings. 2002; 87.
  44. Wang Q, Guo C, Hii G, Shusterman S, Mosse Y, Zhao H, Cnaan A, Hogarty MD and Maris JM. ID2 is a MYCN target gene, but expression is not correlated with MYCN gene amplification in human neuroblastomas. Advances in Neuroblastoma Research Proceedings. 2002; 50.
  45. Maris JM, Guo C, Hii G, Wang Q, Morowitz MJ, Winter C, Mosse Y and Shusterman S. A functional and expression profiling stratefy for isolating neuroblastoma (NB) supressor genes on chromosome 11. Advances in Neuroblastoma Research Proceedings. 2002; 18.
  46. Guo C, Wang Q, Winter CL, Hii G, Morowitz MJ, Mosse Y, Shusterman S and Maris JM. Chromosome 11q23.3-q24.1 deletions in neuroblastoma (NB). Advances in Neuroblastoma Research Proceedings. 2002; 18.
  47. Hii G, Shusterman S, Winter C, Guo C, Wang Q, Mosse Y, Morowitz MJ, Moreau L, Look AT and Maris JM. Prospective validation of real-time quantitative PCR for detection of MYCN amplifcation inprimary neuroblastoma specimens. Advances in Neuroblastoma Research Proceedings. 2002; 67.
  48. Stern JW, Fang J, Shusterman S, Pierson G, Barr R, Pawel B, Diller L, Grupp SA. Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model. Clin Cancer Res. 2001 Apr; 7(4):1026-32. PMID: 11309354.
    Citations: 1     Fields:    Translation:HumansAnimals
  49. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res. 2001 Apr; 7(4):977-84. PMID: 11309349.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  50. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth especially in the setting of subclinical disease. Clinical Cancer Research. 2001; 7(4):977-84.
  51. Shusterman S, Barr R, McMahon G and Maris JM. The growth rate of human neuroblastoma xenografts is decreased through inhibition of multiple angiogenic signaling pathways with SU668. Journal of Pediatric Hematology/Oncology . 2001; 23:A1.
  52. Shusterman S, Barr r, McMahon G and Maris JM. Inhibition of the VEGF, PDGF and bFGF signaling pathways with SU6668 decreases the growth rate of human neuroblastoma xenografts. American Association for Cancer Research Proceedings. 2001; 42:803.
  53. Weiss MJ, Guo C, Shusterman S, Hii G, Mirensky TL, White PS, Hogarty MD, Rebbeck TR, Teare D, Urbanek M, Brodeur GM, Maris JM. Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med Pediatr Oncol. 2000 Dec; 35(6):526-30. PMID: 11107108.
    Citations: 1     Fields:    Translation:HumansCells
  54. Shusterman S, Grupp SA, Maris JM. Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Med Pediatr Oncol. 2000 Dec; 35(6):673-6. PMID: 11107144.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  55. Shusterman S, Meadows AT. Long term survivors of childhood leukemia. Curr Opin Hematol. 2000 Jul; 7(4):217-22. PMID: 10882177.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  56. Grupp SA, Shusterman S, Stern JW, Fang J, Pierson G, Diller L and Maris JM. Inhibitors of angiogenesis in minimal residual disease: safety post-BMT and efficacy in a preclinical model. Angiogenesis in Oncology and Hematology. 2000.
  57. Shusterman S. Microcytic Anemia. Iron Deficiency Anemia. The 5 Minute Pediatric Consult. 2000.
  58. Shusterman S, Guo C and Maris JM. Detection of unbalanced 17q gain in human neuroblastomas by real-time quantitative PCR. American Association for Cancer Research Proceedings. 2000; 41:791.
  59. Eggert A, Ikegaki N, Grotzer MA, Liu X, Kisselbach K, Shusterman S, Ho R, Evans AE and Brodeur GM. Effects of TRK receptor expression on angiogenesis in neuroblastoma cells. American Association for Cancer Research Proceedings. 2000; 41:791.
  60. Shusterman S, Guo C and Maris JM. Use of real-time quantitative PCR to detect unbalanced 17q gain in neuroblastoma cell lines and primary tumors. Medical and Pediatric Oncology. 2000; 35:748.
  61. Shusterman S, Grupp SA and Maris JM. Preclinical evaluation of antiangiogenic therapy with TNP-470 for human neuroblastoma. Molecular Targets and Cancer Therapeutics. 1999; 5:3812s.
  62. Shusterman S, Grupp SA, Kisselbach K and Maris JM. TNP-470 inhibits the growth rate and tumorigenicity of human neuroblastoma xenografts. Journal of Pediatric Hematology/Oncology. 1999; 21:326.
  63. Shusterman S, Palmert MR. A 2.5-month-old girl with hyperbilirubinemia, hypoglycemia, and blindness. Curr Opin Pediatr. 1996 Aug; 8(4):411-6. PMID: 8954277.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Shusterman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (220)
Explore
_
Co-Authors (33)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.